Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2005

View Archived Issues

Hepatitis B virus responses maintained with long-term adefovir therapy

Good PK and safety profile reported for AMG-162 in healthy men

Etanercept reported to reduce bone resorption in psoriatic arthritis

New data on the potential of ferumoxytol as iron replacement therapy

Atheroprotective effects reported for AST-120 in chronic renal failure patients

GCS-100 induces apoptosis in B-cell malignancies

CpG-7909 increases response to first-line chemotherapy in advanced NSCLC

GSK: five vaccine launches in next five years

Organon and Cypress Bioscience partner in obstructive sleep apnea

Rapid enrollment in ragweed allergy study of AIC

Phase II study evaluates picoplatin for small cell lung cancer

Second phase II trial for Hematide in chronic kidney disease patients

Phase I trial for Hsp90 inhibitor IPI-504

rIL-7 studied in HIV in two new phase I studies

OxThera created to advance Q-Med's oxalate project

Positive antitumor efficacy for MMI-166 in a model of lung cancer

Gefitinib/rosiglitazone combination enhances antiproliferative effects in lung cancer cells

Enrollment completed in phase I/II study of smallpox vaccine candidate LC16m8

A novel ORL1 agonist demonstrates efficacy in a model of neuropathic pain

Solvay signs final purchase agreement for Fournier

Arixtra approved in E.U. for prevention of VTE events in abdominal surgery

CE Mark approval for Axxion drug-eluting stent

Fast track status for Fluviral

Drug discovery targets for diabetes

HIV replication inhibitors from Janssen

Cysteine protease inhibitors in early development at Celera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...